Atopic Dermatitis Host and Environment Model: Revisiting Therapeutic Options

• Type: Article in International Scientific Journal
• Date: 2020

Authors

Lopes, A (Author) Other; Sokolova, A (Author) Other; Abreu, C (Author) Other; Lopes, C (Author) FMUP

Journal

Title: European Annals of Allergy and Clinical Immunology

Vol. 52

Pages: 4-14

ISSN: 1764-1489

Publisher: EDRA SPA - LSWR Group

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 1 Citation

Other information

Authenticus ID: P-00R-KN8

DOI: 10.23822/eurannaci.1764-1489.125

Abstract (EN): Atopic Dermatitis affects both children and adults and is a serious health concern in many countries. AD is a complex disease with host and environmentalfactors underlying its pathology. Its treatment is multidimensional reflecting the diverse nature ofits triggers and includes emollients, topical steroids and calcineurin inhibitors among others. Immunological dysfunction can be addressed broadly with systemic immunosupressors and specifically with monoclonal antibodies. Dupilumab, which targets IL-4 and IL-13 was granted approvalfor treatment of moderate-to-severe AD. Biologics targeting IgE/Th2 pathways may have its role in patients with overlapping AD and asthma. Psychological distress can exacerbate symptoms and is associated with increased severity ofAD. Environmental triggers, such as, allergens can be addressed in selected cases with allergic immunotherapy. In this paper, we discuss AD treatment andpropose a new step-by-step approach aiming at maintaining disease control and improving quality of life.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 11